Theratechnologies (TSE:TH) has released an update.
Theratechnologies has reported a robust financial performance for Q3 2024, with an 8% increase in revenue to $22.6 million and a positive net income of $3.1 million. The company also revised its fiscal 2024 revenue guidance to $83-$85 million and increased its Adjusted EBITDA forecast to $17-$19 million, reflecting confidence in continued growth despite a potential temporary supply disruption of their product EGRIFTA SV.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
